Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6911282 | 1.00 | KMT2A (0.57) | KMT2AMEN1CYP1B1ALOX5MAPT | |
| SCHEMBL6908275 | 0.88 | CYP1B1 (0.64) | KMT2AMEN1CYP1B1MAPTSMN1; SMN2 | |
| SCHEMBL7922516 | 0.88 | CYP1B1 (0.64) | KMT2AMEN1CYP1B1MAPTSMN1; SMN2 | |
| SCHEMBL10744603 | 0.85 | KMT2A (0.64) | KMT2AMEN1CYP1B1MAPTSMN1; SMN2 | |
| SCHEMBL10744598 | 0.85 | KMT2A (0.64) | KMT2AMEN1CYP1B1MAPTSMN1; SMN2 | |
| SCHEMBL11432402 | 0.85 | MAOB (0.64) | KMT2AMEN1CYP1B1MAPTSMN1; SMN2 | |
| SCHEMBL6915908 | 0.85 | MAOB (0.64) | KMT2AMEN1CYP1B1MAPTSMN1; SMN2 | |
| SCHEMBL13978652 | 0.84 | KMT2A (0.69) | KMT2AMEN1CYP1B1MAPTSMN1; SMN2 | |
| SCHEMBL5317940 | 0.82 | LMNA (0.65) | KMT2AMEN1CYP1B1MAPTSMN1; SMN2 | |
| SCHEMBL5317936 | 0.82 | LMNA (0.65) | KMT2AMEN1CYP1B1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9122103-B2 | Liquid-crystal display device, process for producing liquid-crystal display device, and composition for forming alignment film | SHARP KABUSHIKI KAISHA (JP) | 2015-09-01 | — | — | US | disclosed |
| US-9122103-B2 | Liquid-crystal display device, process for producing liquid-crystal display device, and composition for forming alignment film | SHARP KABUSHIKI KAISHA (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20120314166-A1 | LIQUID-CRYSTAL DISPLAY DEVICE, PROCESS FOR PRODUCING LIQUID-CRYSTAL DISPLAY DEVICE, AND COMPOSITION FOR FORMING ALIGNMENT FILM | SHARP KABUSHIKI KAISHA (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120314166-A1 | LIQUID-CRYSTAL DISPLAY DEVICE, PROCESS FOR PRODUCING LIQUID-CRYSTAL DISPLAY DEVICE, AND COMPOSITION FOR FORMING ALIGNMENT FILM | SHARP KABUSHIKI KAISHA (JP) | 2012-12-13 | — | — | US | disclosed |
| US-6689899-B2 | HYDROGENATION OF THE CORRESPONDING DINITRO COMPOUNDS | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-02-10 | — | — | US | disclosed |
| US-20020019558-A1 | Diamine and acid anhydride | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019558-A1 | Diamine and acid anhydride | CA1, ASIC1, CA4 | KMT2A 679/4885MEN1 1404/4885CYP1B1 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.